Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, LTD. (KAPA) on June 3, 2025. The Company is a Delaware corporation incorporated as an emerging growth company, with its principal executive offices in Los Angeles, California. The report addresses a specific corporate event occurring on the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this filing. The primary event is the announcement that Chief Executive Officer Dr. John Yu will present data on the Company's investigational small molecule GITR ligand agonist, KROS101, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
Guidance, Outlook, and Risks
The Company highlighted upcoming clinical data presentation at the ASCO 2025 Annual Meeting, held from May 30 to June 3, 2025, in Chicago, Illinois. No specific financial guidance, risk factors, or contingencies were detailed in this specific 8-K text, other than the standard disclosure of the press release furnished as Exhibit 99.1.
Investor Verification Checklist
- Verify the content of the press release furnished as Exhibit 99.1 for specific clinical data details on KROS101.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting.
- Monitor subsequent filings for any financial impact or strategic shifts resulting from the ASCO 2025 data presentation.